There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
REGULATORY
Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
Japan has reported four new “probable” cases of children with acute hepatitis of unknown etiology, bringing the total number of such detections to 62, the Japanese health ministry said on June 24. In its latest update, the Ministry of Health,…
To read the full story
Related Article
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
May 9, 2022
REGULATORY
- New Panel on Drug Distribution and Pricing Likely to Launch on Aug. 31
August 18, 2022
- AZ’s Asthma Drug Tezepelumab Up for MHLW Panel Review on August 29
August 17, 2022
- Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December
August 16, 2022
- Authorized Generics Approved for Nexium, Samsca, Lipitor, Careram
August 16, 2022
- First Generics for 5 APIs Approved towards December Listing, with 8 Firms for Nexium
August 16, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…